MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase III drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how MRG-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MRG-002 overview

MRG-002 is under development for the treatment of gastric cancer, HER2-positive metastatic breast cancer, human epidermal growth factor receptor 2 negative breast cancer (HER2- Breast Cancer), advanced or metastatic biliary adenocarcinoma, recurrent or metastatic breast cancer, gastroesophageal (GE) junction carcinomas, advanced or metastatic urothelial carcinoma including bladder cancer, urethral cancer, ureter cancer, salivary gland cancer, esophageal cancer, breast cancer and HER2-expressing advanced malignant solid tumors. It is administered through intravenous route. The drug candidate is an antibody-drug conjugate which is developed by based on ADC technology. The therapeutic candidate acts by targeting HER-2.

It was under development for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC), squamous non-small cell lung carcinoma and Metastatic Biliary Tract Cancer.

Shanghai Miracogen overview

Shanghai Miracogen., biotechnology company that offers development, clinical research and industrialization of new cancer targeted therapy drugs-the world’s cutting-edge technology Antibody Drug Conjugate (ADC) and innovative antibody anti-tumor drugs

For a complete picture of MRG-002’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.